Denver activists, police officials and other experts have agreed upon a set of recommendations to expand the city’s historic vote to decriminalize psilocybin in 2019—including by deprioritizing criminal enforcement against additional activities like gifting and communal use of the fungi.
Cybin files a new patent application in support of the development of drug candidate CYB004.
Psychedelic stocks today are cash-rich with extremely attractive valuations. Blue-chip stocks sit with record debt levels and grossly inflated valuations. Advantage: psychedelic stocks.
Novamind is expanding its mental health care to include the treatment of patients with palliative needs, via its new Murray, Utah treatment clinic.
PharmaTher initiates a Phase 2a clinical trial for a ketamine-based therapy for Parkinson's Disease, expected to commence in October 2021.
A congressman said on Wednesday that he intends to help bring the psychedelics reform movement to Capitol Hill “this year.”
Mydecine's lead drug candidate, MYCO-001 will be used in a major, new smoking cessation clinical study by Johns Hopkins.
Optimi Health files a provisional patent application for a stable extraction method for natural psilocybin.
Levitee Labs reports (unaudited) revenues of CAD$893,863 for the month of August from clinic operations.
The Schedule I classification for psychedelic drugs needs to be changed. But to what -- and when? Psychedelic Stock Watch takes a broad look at that question.
Seattle’s City Council approved a resolution Monday to decriminalize noncommercial activity around a wide range of psychedelic substances, including the cultivation and sharing of psilocybin mushrooms, ayahuasca, ibogaine and non-peyote-derived mescaline.
Mydecine spins out the company's cannabis assets into a private subsidiary, to comply with with the regulatory requirements of both the NASDAQ and London Stock Exchange.
